Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Neoantigens are crucial for individualized cancer vaccines due to their immunogenicity.
• Advances in computational algorithms and machine learning enhance neoantigen prediction accuracy.
• Clinical trials show promise for neoantigen-based vaccines across various platforms.

Purpose of the Study:

• To provide an overview of neoantigen identification methodologies.
• To discuss advances in prediction and validation strategies for neoantigens.
• To explore the interplay of tumor-intrinsic and immune factors influencing neoantigen expression.

Main Methods:

• Review of current computational algorithms and machine learning for neoantigen prediction.
• Analysis of validation systems for assessing neoantigen-induced cytotoxic T lymphocyte activation.
• Examination of tumor-intrinsic factors (e.g., ARID1A mutations, PD-L1 expression) and therapeutic influences on neoantigenicity.

Main Results:

• Improved accuracy in neoantigen prediction through advanced computational methods.
• Identification of non-coding RNA-derived neoantigens alongside conventional mutations.
• Understanding of how factors like ARID1A mutations and PD-L1 expression modulate neoantigen presentation and immune response.

Conclusions:

• Neoantigen identification and validation remain complex but are advancing rapidly.
• Tumor-intrinsic and therapeutic factors dynamically regulate neoantigen expression and immunogenicity.
• Neoantigen-based therapies hold significant potential to revolutionize cancer immunotherapy.